Curriculum Vitae
Medical geneticist, solid tumor oncogenetics and AI applied to genomics.
Abdelhakim BOUAZZAOUI
is a medical geneticist
Currently at Montpellier University Hospital, within the Molecular Medicine and Genomics Platform, Solid Tumor Biology sector.
His work sits at the intersection of oncogenetics, clinical genomics and artificial intelligence tools applied to high-throughput sequencing data interpretation.
The main interest: understanding how machine learning and deep learning can help prioritize, interpret and clarify complex genomic data, without losing the clinical rigor required for medical decision-making.
Current Position
- Montpellier University Hospital, Molecular Medicine and Genomics Platform.
- Solid Tumor Biology sector.
- Ongoing PhD in Health Biology — Inserm U1194, IRCM Montpellier (Dr Peter Coopman): multimodal AI applied to solid tumors.
- Current activity in solid tumor oncogenetics.
- Main scientific interest: AI applied to clinical genomics, variant interpretation and whole-genome data.
Training
- PhD in Health Biology, ongoing since November 2025 — Inserm U1194, IRCM Montpellier (Dr Peter Coopman).
- Medical Genetics residency, started in 2021.
- Master’s degree in Bioinformatics and Computational Biology, 2024.
- University Diploma in High-Throughput Sequencing and Bioinformatics, University of Bordeaux, 2024.
- Inter-University Diploma in Medical Cytogenetics, Université Paris-Cité, 2023.
- Inter-University Diploma in Dysmorphology, Developmental Anomalies and Malformation Syndromes, 2022.
- Master’s level training in Health Biology, Genetics and Mathematics.
- Medical studies, Faculty of Medicine of Limoges.
Clinical and Hospital Background
- Medical genetics, clinical genetics, cytogenetics, molecular genetics and genomics.
- Experience in oncogenetics, constitutional genomics, ophthalmic genetics and rare diseases.
- Clinical rotations and inter-university hospital placements, including Rennes, Nantes and Toulouse University Hospitals.
Selected Work
Publications:
- MobiDeep: an AI-based meta-score for scoring non-coding DNA variations.
- Expanding the TUBB3-related phenotypic landscape.
- Assisted reproductive technology, congenital malformations and postnatal health.
- Contributions in genetic epilepsy, ocular developmental anomalies, SHOX and molecular cytogenetics.
Projects:
- Onkogene.com: digital project at the interface of oncogenetics, genomics and clinical tools.
- MobiDeep: AI meta-score for non-coding variant prioritization.
Talks:
- 13th French Meeting of Human and Medical Genetics, 2026: non-coding variant prioritization and MobiDeep.
- BioInfoDiag workshop at the 13th French Meeting of Human and Medical Genetics, 2026: co-organized a 90-minute session on large language models in genetics (150 participants).
- Western France Genetics Seminar, 2025: MobiDeep.
- BioInfoDiag API-hour, 2025: MobiDeep.
- EuroDysmorpho, Ljubljana, 2024: French cohort of male BPAN patients.
- Western France Genetics Seminar, 2022: TUBB3 and intrafamilial variability.
- EuroDysmorpho, 2022: TUBB3 in prenatal diagnosis.
Media
- Institutional articles about MobiDeep, Fondation Groupama and Fonds Guilhem.
- Recorded talks about tubulinopathies and MobiDeep.
Grants and Distinctions
- Michel Goossens grant, ANPGM, 2025.
- Fondation Groupama Rare Diseases funding, 2025, for a bioinformatics and molecular genetics research project.